1.
Practical Oncology Journal
; (6): 183-187, 2019.
文章
在 中文
| WPRIM
| ID: wpr-752836
摘要
Diffuse large B-cell lymphoma(DLBCL) is a group of highly heterogeneous diseases with unique pathological characteristics and genetic changes,and the prognosis of patients depends largely on this. With the development of precision medicine, it is especially important to identify high-risk patients earlier and provides related treatments to prolong the survival time of patients and improves their quality of life. In recent years,DLBCL prognosis-related laboratory markers has progressed to more effectively pre-dict patient prognosis and guides clinical treatment. This review summarizes the recent advances in laboratory markers in the prognosis of DLBCL.